Abstract
Relationship between biological responses and binding affinities at I1/I2/I3 imidazoline receptors of compounds with imidazoline, pyrroline or oxazoline moieties was studied by 2D-QSAR, 3D-QSAR and quantitative pharmacophore development approaches. Since the I1 imidazoline receptor is involved in central inhibition of sympathicus that produce hypotensive effect, the I2 receptor is allosteric modulator of monoamine oxidase B (MAO-B) and the I3 receptor regulates insulin secretion from pancreatic β-cells, design and synthesis of selective I1/I2/I3 imidazoline ligands are very important for the development of new effective therapeutic agents. New agonists and antagonists with high selectivity for I1/I2/I3 imidazoline receptor classes have been recently synthesized and examined. The present review will highlight the main chemical diversity and pharmacophore features of selective I1/I2/I3 imidazoline receptor ligands.
Keywords: I1-imidazoline receptors, I2-imidazoline receptors, I3-imidazoline receptors, hypotensive, enzymes, phenylethanolamine-Nmethyl, imidazoline, imidazole-4-acetic, agmatine, lipophilicity
Mini-Reviews in Medicinal Chemistry
Title:Pharmacophore Development and SAR Studies of Imidazoline Receptor Ligands
Volume: 12 Issue: 14
Author(s): Katarina Nikolic and Danica Agbaba
Affiliation:
Keywords: I1-imidazoline receptors, I2-imidazoline receptors, I3-imidazoline receptors, hypotensive, enzymes, phenylethanolamine-Nmethyl, imidazoline, imidazole-4-acetic, agmatine, lipophilicity
Abstract: Relationship between biological responses and binding affinities at I1/I2/I3 imidazoline receptors of compounds with imidazoline, pyrroline or oxazoline moieties was studied by 2D-QSAR, 3D-QSAR and quantitative pharmacophore development approaches. Since the I1 imidazoline receptor is involved in central inhibition of sympathicus that produce hypotensive effect, the I2 receptor is allosteric modulator of monoamine oxidase B (MAO-B) and the I3 receptor regulates insulin secretion from pancreatic β-cells, design and synthesis of selective I1/I2/I3 imidazoline ligands are very important for the development of new effective therapeutic agents. New agonists and antagonists with high selectivity for I1/I2/I3 imidazoline receptor classes have been recently synthesized and examined. The present review will highlight the main chemical diversity and pharmacophore features of selective I1/I2/I3 imidazoline receptor ligands.
Export Options
About this article
Cite this article as:
Nikolic Katarina and Agbaba Danica, Pharmacophore Development and SAR Studies of Imidazoline Receptor Ligands, Mini-Reviews in Medicinal Chemistry 2012; 12 (14) . https://dx.doi.org/10.2174/138955712803832636
DOI https://dx.doi.org/10.2174/138955712803832636 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation of Angiotensin II Receptor Expression
Current Pharmaceutical Design Role of Hydrogen Sulfide in Systemic and Pulmonary Hypertension: Cellular Mechanisms and Therapeutic Implications
Cardiovascular & Hematological Agents in Medicinal Chemistry Midazolam Plus Haloperidol as Adjuvant Analgesics to Morphine in Opium Dependent Patients: A Randomized Clinical Trial
Current Drug Abuse Reviews Nutraceuticals for Promoting Longevity
Current Nutraceuticals Supramolecular Chiro-Biomedical Aspect of β-Blockers in Drug Development
Current Drug Targets New Therapies in SLE
Recent Patents on Inflammation & Allergy Drug Discovery Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets High Throughput Screening and Structure-Activity Relationship Study of Potential α2A-Adrenoceptor Agonists by LANCETM cAMP Assay
Combinatorial Chemistry & High Throughput Screening HIF Prolyl 4-Hydroxylases and their Potential as Drug Targets
Current Pharmaceutical Design Targeting <i>Plasmodium Metabolism</i> to Improve Antimalarial Drug Design
Current Protein & Peptide Science The Blockade of Renin-Angiotensin-Aldosterone System in Hemodialysis Patients to Control Hypertension and Prevent Cardiovascular Disease: Optimal Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Implications of Angiotensin II in Central Nervous System on Exercise Performance
Current Protein & Peptide Science Monoclonal Antibodies as Cancer Therapeutics
Recent Patents on Biotechnology Transformation of UPLC-MS Data Overcomes Extreme Variability in Urine Concentration and Metabolite Fold Change
Current Metabolomics Study of Convolvulus pluricaulis for Antioxidant and Anticonvulsant Activity
Central Nervous System Agents in Medicinal Chemistry Psychiatric Disorders Associated with FXTAS
Current Psychiatry Reviews Susceptibility Genes in Hypertension
Current Pharmaceutical Design Artery of Percheron Infarction: A Characteristic Pattern of Ischemia and Variable Clinical Presentation: A Literature Review
Current Medical Imaging Editorial: Perioperative Pharmacological Management: From Prescription Medications to Dietary Supplements
Current Clinical Pharmacology TRP Channels: Emerging Links Between Ca2+, Kidney and Hypertension
Current Hypertension Reviews